×
Key messages
Background
Findings
Perspectives
Expert commentary
Go back
|
list
format_size
dark_mode
Perspectives
How does this study impact clinical practice?
No new safety issues were identified with multiple doses of 200 mg and 400 mg lasmiditan.
Lasmiditan does not appear to inhibit or induce the activities of CYP1A2, CYP2C9 or CYP3A.
